| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2012-03-15 | FerroKin BioSciences (USA) | Shire (UK - USA) | up to $225 million (€171.7 million), depending upon the achievement of certain clinical development, regulatory and net sales targets | Hematology |
| 2012-03-05 | Epitomics (USA) | Abcam (UK) | $155 million (€117.2 million) | Antibody technologies |
| 2012-03-01 | Pierrel Research International (CRO business of Pierrel) (Italy) | mondoBIOTECH (Switzerland) | CRO |
|
| 2012-02-28 | Anabasis (italy) | Dompé (italy) | Ophtalmological diseases |
|
| 2012-02-17 | Amsterdam Molecular Therapeutics (The Netherlands) | uniQure BV (The Netherlands) | Gene therapy |
|
| 2012-02-14 | Nexus Oncology (UK) | Ockham (USA) | CRO |
|
| 2012-01-26 | Micromet (USA - Germany) | Amgen (USA) | $1.16 billion (€0.88 billion) | Oncology |
| 2012-01-25 | Illumina (USA) | Roche (Switzerland) | $6.8 billion (€5.13 million) | diagnostics NGS |
| 2012-01-20 | Warwick Effect Polymers (UK) | PolyTherics (UK) | undisclosed | Protein and peptide-based drugs |
| 2011-12-16 | Topotarget USA (Topotarget’ American subsidiary division - Denmark) | Apricus Biosciences (USA) | up to $4 million | Cancer Oncology |
| 2011-12-08 | Advanced Bio-Technologies (USA) | Sinclair IS Pharma (UK) | £21 million (€24.5 milion) | Dermatology |
| 2011-12-02 | Verum Diagnostica (Germany) | Roche (Switzerland) | € 13 million (€ 11 million and potentially a further € 2 million contingent upon reaching certain performance-related milestones) | Clinical diagnostic |
| 2011-12-02 | PharmaPack International (The Netherlands) | Actavis (Switzerland) | undisclosed | Pharmaceutical packaging |
| 2011-11-22 | Lectus Therapeutics (UK) | UCB (Belgium) | undisclosed | CNS diseases |
| 2011-11-04 | Cellartis (Sweden) | Cellectis (France) | € 30 million in shares and cash | Stem cells |
| 2011-11-02 | Anadys Pharmaceuticals (USA) | Roche (Switzerland) | $ 230 million (€ 167,47 million) | |
| 2011-10-31 | Cobra Biologics (UK) | Unitech Pharma Group (Sweden) | ||
| 2011-10-27 | DuoCort Pharma (Sweden) | Viropharma (USA) | up to $131 million | drug industry |
| 2011-10-20 | Arch Chemicals (USA) | Lonza (Switzerland) | $ 1.4 billion (€ 0.97,billion) | Microbial control |
| 2011-10-20 | Macrocyclics (USA) | Areva (France) | undisclosed | Nuclear medicine |
